XML 123 R66.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Financial assets and liabilities measured at fair value (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Fair Value Measurement [Abstract] |
Summary of Assets and Liabilities Measured at Fair Value | The table below shows the balance sheet amounts of assets and liabilities measured at fair value.
|  | 2024 | 2023 | 2022
|  | Level in the fair value hierarchy | Level in the fair value hierarchy | Level in the fair value hierarchy
(€ million) | Note | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3
Financial assets measured at fair value |  |  |  |  |  |  |  |  |  |
Quoted equity investments | D.7.1. | 467 | — | — | 470 | — | — | 387 | — | —
Unquoted equity investments | D.7.1. | — | — | 1,092 | — | — | 618 | — | — | 549
Quoted debt securities | D.7.2. | 357 | — | — | 346 | — | — | 329 | — | —
Unquoted debt securities not meeting the definition of equity instruments | D.7.3. | — | — | 339 | — | — | 132 | — | — | 115
Contingent consideration relating to divestments | D.7.3. & D.11. | — | — | 286 | — | — | 214 | — | — | 303
Financial assets held to meet obligations under deferred compensation plans | D.7.3. & D.11. | 688 | — | — | 572 | — | — | 512 | — | —
Non-current derivatives | D.7. | — | — | — | — | — | — | — | — | —
Current derivatives | D.11. | — | 217 | — | — | 201 | — | — | 206 | —
Mutual fund investments | D.13. | 4,161 | — | — | 5,349 | — | — | 9,537 | — | —
Total financial assets measured at fair value |  | 5,673 | 217 | 1,717 | 6,737 | 201 | 964 | 10,765 | 206 | 967
Financial liabilities measured at fair value |  |  |  |  |  |  |  |  |  |
Bayer contingent purchase consideration arising from the acquisition of Genzyme | D.18. | — | — | — | — | — | — | — | — | 26
MSD contingent consideration (European vaccines business) | D.18. | — | — | 72 | — | — | 127 | — | — | 204
Shire contingent consideration arising from the acquisition of Translate Bio | D.18. | — | — | 568 | — | — | 441 | — | — | 380
Contingent consideration arising from acquisition of Amunix | D.18. | — | — | — | — | — | 137 | — | — | 165
Other contingent consideration arising from business combinations and acquisitions | D.18. | — | — | 1 | — | — | 4 | — | — | 4
Non-current derivatives | D.20. | — | 121 | — | — | 164 | — | — | 232 | —
Current derivatives | D.19.5 | — | 337 | — | — | 127 | — | — | 94 | —
Total financial liabilities measured at fair value |  | — | 458 | 641 | — | 291 | 709 | — | 326 | 779

X
- Definition Disclosure of fair value of financial assets and liabilities explanatory. + References No definition available. + Details
Name: | sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Measurement [Abstract] + References No definition available. + Details
Name: | sny_FairValueMeasurementAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration